<meta charset="UTF-8"/>
<meta name="tikaGenerated" content="true"/>
<meta name="date" content="2020-04-07T23:33:52Z"/>
<meta name="xmp:CreatorTool" content="Acrobat PDFMaker 15 for Word"/>
<meta name="Company" content="SA Health"/>
<meta name="Keywords" content="Neonatal Medication Guideline, aspirin, thromboprophylaxis"/>
<meta name="subject" content="Neonatal Medication Guideline"/>
<meta name="dc:creator" content="SA Maternal, Neonatal & Gynaecology Community of Practice"/>
<meta name="dcterms:created" content="2020-04-07T23:33:50Z"/>
<meta name="Last-Modified" content="2020-04-07T23:33:52Z"/>
<meta name="dcterms:modified" content="2020-04-07T23:33:52Z"/>
<meta name="title" content="Aspirin"/>
<meta name="Last-Save-Date" content="2020-04-07T23:33:52Z"/>
<meta name="meta:save-date" content="2020-04-07T23:33:52Z"/>
<meta name="dc:title" content="Aspirin"/>
<meta name="modified" content="2020-04-07T23:33:52Z"/>
<meta name="cp:subject" content="Neonatal Medication Guideline"/>
<meta name="Content-Type" content="application/pdf"/>
<meta name="creator" content="SA Maternal, Neonatal & Gynaecology Community of Practice"/>
<meta name="meta:author" content="SA Maternal, Neonatal & Gynaecology Community of Practice"/>
<meta name="dc:subject" content="Neonatal Medication Guideline, aspirin, thromboprophylaxis"/>
<meta name="meta:creation-date" content="2020-04-07T23:33:50Z"/>
<meta name="created" content="Wed Apr 08 09:03:50 ACST 2020"/>
<meta name="xmpTPg:NPages" content="2"/>
<meta name="Creation-Date" content="2020-04-07T23:33:50Z"/>
<meta name="SourceModified" content="D:20200407230313"/>
<meta name="meta:keyword" content="Neonatal Medication Guideline, aspirin, thromboprophylaxis"/>
<meta name="Author" content="SA Maternal, Neonatal & Gynaecology Community of Practice"/>
<meta name="producer" content="Adobe PDF Library 15.0"/>
South Australian Neonatal Medication Guidelines 

 300mg soluble tablet 

  Department for Health and Wellbeing, Government of South Australia. All rights reserved. 



This guideline provides advice of a general nature.  This statewide guideline has been prepared to promote and facilitate 
standardisation and consistency of practice, using a multidisciplinary approach.  The guideline is based on a review of 
published evidence and expert opinion.  
Information in this statewide guideline is current at the time of publication.  
SA Health does not accept responsibility for the quality or accuracy of material on websites linked from this site and does not 
sponsor, approve or endorse materials on such links. 
Health practitioners in the South Australian public health sector are expected to review specific details of each patient and 
professionally assess the applicability of the relevant guideline to that clinical situation. 
If for good clinical reasons, a decision is made to depart from the guideline, the responsible clinician must document in the 
patient s medical record, the decision made, by whom, and detailed reasons for the departure from the guideline. 
This statewide guideline does not address all the elements of clinical practice and assumes that the individual clinicians are 
responsible for discussing care with consumers in an environment that is culturally appropriate and which enables respectful 
confidential discussion. This includes: 

  The use of interpreter services where necessary, 
  Advising consumers of their choice and ensuring informed consent is obtained, 
  Providing care within scope of practice, meeting all legislative requirements and maintaining standards of 

professional conduct, and  
  Documenting all care in accordance with mandatory and local requirements 

Dose and Indications  

Thromboprophylaxis post cardiac surgery 
1 to 5mg/kg once daily  

Preparation and Administration 


Disperse a 300mg tablet in 30mL of sterile water; this will give a 10mg/mL aspirin mixture.  

The mixture should be stirred intermittently for a few minutes while dispersing. Before 
withdrawing dose,  pump  the mixture in and out of the syringe four times to ensure the best 
possible drug distribution. 

Dose 1mg 2mg 3mg 4mg 5mg 

Volume 0.1mL 0.2mL 0.3mL 0.4mL 0.5mL 

Withdraw dose and administer immediately. Use a fresh tablet for each dose and discard any 
remaining solution. 

Adverse Effects 

Nausea, vomiting, abdominal pain, gastrointestinal upset, asymptomatic blood loss 

Dyspnoea, rhinitis, severe cutaneous adverse reactions (SCARs), skin reactions, 
gastrointestinal haemorrhage 

South Australian Neonatal Medication Guidelines 

 300mg soluble tablet 




Reye s syndrome (more common with doses &gt;40mg/kg/day), aplastic anaemia, erythema 
nodosum, granulocytosis, haemorrhagic vasculitis, intracranial haemorrhage, nausea, 
thrombocytopenia, vomiting 

Allergic reaction 

Bronchospasm, angioedema, urticaria and rhinitis have been precipitated by aspirin; there is 
cross-reactivity with other non-steroidal anti-inflammatory drugs (NSAIDs) 

&gt; Monitor for symptoms of salicylism including sweating, vomiting, nasal congestion and 

slight hyperpyrexia. Symptoms of severe salicylate toxicity include hyperventilation, 
restlessness, irritability, hyperthermia and alterations in acid-base balance, primarily 
respiratory alkalosis. 

Practice Points 
&gt; The use of aspirin in infants for the treatment of fever and muscle ache associated with 

viral illness should be avoided due to the association with Reye s syndrome 

&gt; Use with caution in renal impairment, allergic disease, anaemia, dehydration, G6PD 
deficiency, thyrotoxicosis, uncontrolled hypertension and thrombocytopenia 

&gt; Contraindicated in severe active bleeding or disease states with an increased risk of 
severe bleeding (e.g. bleeding disorders, erosive gastritis or peptic ulcer disease, severe 
hepatic disease, allergy to aspirin or NSAIDs) 

Practice Points 
&gt; Brustugun J, et al, Adjusting the dose in paediatric care: dispersing four different aspirin 

tablets and taking a portion, European Journal of Hospital Pharmacy, 2019 

Document Ownership &amp; History 
Developed by: SA Maternal, Neonatal &amp; Gynaecology Community of Practice 
Contact: Health.NeoMed@sa.gov.au 
Endorsed by:  SA Health Safety and Quality Strategic Governance Committee 
Next review due:   03/04/2025 
ISBN number:  978-1-76083-175-2 
PDS reference:  CG332 
Policy history: Is this a new policy (V1)?  Y 
 Does this policy amend or update and existing policy?   N 
 If so, which version? 
 Does this policy replace another policy with a different title?  N 

Date Version Who approved New/Revised Version Reason for Change 

03/04/2020  V1 SA Health Commissioning and Performance Division Original approved version